Clinical trials: Ulcerative Colitis, Unspecified
Colitis, Ulcerative
A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis
The purpose of this study is to examine the safety and efficacy of OPC-6535 (tetomilast) and to determine its optimal dose by once-daily oral administration at 0, 12.5, 25, or 50 mg for 8 weeks in combination with a fixed oral…
- Trial name
- NCT00317356
- Testing
- OPC-6535(Tetomilast)
- Where
- 8 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Ulcerative Colitis
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
The main objectives of this study were to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of vedolizumab in patients with ulcerative colitis (UC).
- Trial name
- NCT01177228
- Testing
- Vedolizumab
- Volunteers
- 47 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- EMERALD-2 (NCT05611671)
- Testing
- MORF-057
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 280 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Ulcerative Colitis
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active…
- Trial name
- NCT03093259
- Testing
- ABX464
- Where
- 19 sites in Austria, Belgium and 6 more
- Volunteers
- 32 people
- Sponsor
- Abivax S.A.
Inflammatory Bowel Disease, Ulcerative Colitis
Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory bowel disease (IBD) is an important cause of loss of response to therapy that may lead to escalation of dose or discontinuation of therapy.
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
- Trial name
- NCT02413047
- Testing
- Azathioprine, 6 mercaptopurine, Methotrexate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Indiana University
Ulcerative Colitis
Special Investigation in Patients With Ulcerative Colitis
This investigation will be conducted to obtain the following information regarding the use of Humira 40 mg Syringe 0.8 mL for Subcutaneous Injection in patients with Ulcerative Colitis. 1.
- Trial name
- NCT01947816
- Volunteers
- 1,621 people
- Sponsor
- AbbVie
Crohn's Disease, Ulcerative Colitis
To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)
An observational, prospective cohort study to evaluate the safety and efficacy of Remsima™ in patients with Crohn's disease (CD) or Ulcerative Colitis (UC)
- Trial name
- NCT02326155
- Volunteers
- 470 people
- Sponsor
- Celltrion
Ulcerative Colitis, Healthy
GI Permeability Change in Response to Aquamin®
This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people…
- Conditions
- Ulcerative Colitis, Healthy, Irritable Bowel Syndrome With Diarrhea
- Trial name
- NCT04855799
- Testing
- Aquamin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- James Varani
Inflammatory Bowel Disease, Ulcerative Colitis
The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis
The purpose of this study is to determine if home automated telemanagement improves bowel symptoms, quality of life, compliance with medications, and health care utilization compared to best available care in patients with…
- Trial name
- UCHAT (NCT00620126)
- Testing
- UC Home Automated Telemanagement, Best Available Care
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Maryland, Baltimore